Lifecore Signs 10-Year CDMO Deal to Support Ophthalmic Drug Commercialisation

• Lifecore Biomedical has signed a 10-year commercial manufacturing and supply agreement with an existing client to advance a novel ophthalmic therapy.

• The deal includes a multi-million-dollar statement of work for fill and finish CDMO services, including PPQ batch manufacturing.

Lifecore Biomedical, Inc., a fully integrated contract development and manufacturing organization (CDMO), has entered into a new 10-year commercial manufacturing and supply agreement with an existing client. The collaboration supports the continued development and future commercialisation of a novel ophthalmic therapeutic.

The agreement is part of Lifecore’s strategy to convert its late-stage customer pipeline into commercial revenue. “The signing of this long-term commercial supply agreement with one of those customers is a critical step on our path to recognizing impactful commercial manufacturing revenue from this longstanding relationship,” said Paul Josephs, chief executive officer of Lifecore.

Alongside the supply agreement, Lifecore has signed a multi-million-dollar statement of work. This covers a range of fill and finish CDMO services that are intended to prepare the product for regulatory submission and commercial launch. The scope includes the manufacture of multiple Process Performance Qualification (PPQ) batches.